Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety and tolerability of Nintedanib in patients with
bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell
transplantation. All study patients with BOS will be treated with the study drug Nintedanib
(300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months
treatment period.